In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

RIO-Reopro, peripheral arterial intervention, outcome

Peripheral Arterial Diseases

Discussant Report:

The investigators made assumptions about thromboembolic complications of elective peripheral interventions based on the published results. They developed a concept to prevent these complications with abciximab (ReoPro) and conducted a randomized multicenter trial.

This trial failed its primary combined endpoint death, amputation, re-intervention or occlusion at 30 days.
There was a significant reduction of intraprocedural peripheral embolism and a significant reduction in 6 months target vessel occlusion but also a five-fold increase of severe bleeding complications.

This trial was very well designed and carefully conducted. Although the primary endpoint failed, there was some improvement with ReoPro, which was not only statistically significant but also clinically relevant. However, bleeding complications are a major cause of morbidity and mortality of peripheral interventions. Therefore the observed increase in bleeding complications is not acceptable. It is unclear whether the bleeding complications could be reduced by modified access site management. According to these results, ReoPro seems not to be indicated in elective peripheral interventions. It may be that sub-group analyses (diabetes?) will give more insights.




Reopro and peripheral arterial intervention to improve clinical outcome in patients with peripheral arterial disease (RIO-Trial).

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.